Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 871 to 880 of 1334 total matches.
New Monoclonal Antibodies to Prevent Transplant Rejection
The Medical Letter on Drugs and Therapeutics • Sep 25, 1998 (Issue 1036)
bind to the α
chain of the IL-2 receptor, blocking IL-2 mediated activation of T-lymphocytes with only ...
Basiliximab (Simulect - Novartis) and daclizumab (Zenapax - Roche), two mouse/human monoclonal antibodies that block the interleukin-2 (IL-2) receptor on Tlymphocytes, have been approved by the FDA for use in the prevention of acute renal transplant rejection. Both drugs are used with cyclosporine (Sandimmune; Neoral) and corticosteroids. An all-murine anti-CD3 monoclonal antibody, muromonab-CD3 (Orthoclone OKT3), has been available in the USA for many years for treatment of transplant rejection, and has also been used with some success for prophylaxis (MI Wilde and KL Goa, Drugs,...
Thalidomide
The Medical Letter on Drugs and Therapeutics • Oct 23, 1998 (Issue 1038)
and
oral ulcers in HIV-positive patients, and may be active in other inflammatory conditions as well ...
Thalidomide (Thalomid - Celgene), a synthetic derivative of glutamic acid, has been approved by the FDA for use in treatment of leprosy. Thalidomide was marketed in Europe in 1957 as a sedative but withdrawn four years later after being associated with severe human teratogenicity. The drug has since been found to be effective for several different indications.
Candesartan for Hypertension
The Medical Letter on Drugs and Therapeutics • Nov 20, 1998 (Issue 1040)
hydrolyzed to its active metabolite candesartan, reaching peak plasma concentrations in three to four hours ...
Candesartan cilexetil (Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension.
Growth-Hormone-Releasing-Factor for Growth Hormone Deficiency
The Medical Letter on Drugs and Therapeutics • Jan 01, 1999 (Issue 1043)
have full biological activity. Administration of GHRH in repeated boluses stimulates release of growth ...
Sermorelin acetate, a synthetic form of human growth-hormone-releasing factor has been approved by the FDA for treatment of idiopathic growth hormone deficiency in children with growth failure.
Miglitol for Type 2 Diabetes Mellitus
The Medical Letter on Drugs and Therapeutics • May 21, 1999 (Issue 1053)
diminish with time. Increased aminotransferase activity has not been reported with miglitol. Low
serum ...
Miglitol, an oral alpha-glucosidase inhibitor similar to acarbase, is now available for treatment of type 2 diabetes.
A New Conjugated Estrogen
The Medical Letter on Drugs and Therapeutics • Jul 30, 1999 (Issue 1058)
or uterine cancer, women with undiagnosed vaginal bleeding, active thrombophlebitis or thromboembolic ...
A new synthetic conjugated estrogen product (Cenestin - Duramed) was recently approved by the US Food and Drug Administration for treatment of vasomotor symptoms due to estrogen deficiency.
Malathion for the Treatment of Head Lice
The Medical Letter on Drugs and Therapeutics • Aug 13, 1999 (Issue 1059)
, 1998; HR Contreras and E Bustos-Obregón, J Exp Zool, 284:355, 1999).
ACTIVITY — Malathion 0.5 ...
0.5% malathion in 78% isopropanol was recently approved by the FDA for treatment of head lice.
Cevimeline (Evoxac) For Dry Mouth
The Medical Letter on Drugs and Therapeutics • Aug 07, 2000 (Issue 1084)
of antimuscarinic drugs such as atropine or scopolamine. Patients with poor CYP2D6 activity may
have a higher risk ...
Cevimeline hydrochloride, an acetylcholine derivative, has been approved by the FDA for treatment of dry mouth symptoms caused by Sjogren's syndrome. Presumably it could also be used to treat radiation-induced xerostomia in patients with head and neck cancer. Pilocarpine hydrochloride is FDA-approved for both indications
Eflornithine Cream For Facial Hair Reduction
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000 (Issue 1089)
procedures were needed less frequently. The difference between the active
drug and placebo was detectable ...
Eflornithine hydrochloride cream 13.9% (Vaniqa - Bristol-Myers Squibb) has been approved by the FDA for reduction of unwanted facial hair in women.
Ortho Evra - A Contraceptive Patch
The Medical Letter on Drugs and Therapeutics • Jan 21, 2002 (Issue 1122)
mg of the progestin norelgestromin (the active metabolite
of norgestimate) and 0.75 mg of ethinyl ...
A transdermal contraceptive patch (Ortho Evra — Ortho-McNeil) has been approved by the FDA. Each 20 cm2 patch contains 6 mg of the progestin norelgestromin (the active metabolite of norgestimate) and 0.75 mg of ethinyl estradiol.